✦ LIBER ✦

PO10-TU-39 Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

✍ Scribed by S. Cook; P. Vermersch; G. Comi; G. Giovannoni; K. Rammohan; P. Rieckmann; P. Soelberg-Sørensen; P. Chang; A. Hamlett; B. Musch; V. Viglietta; S. Greenberg

Book ID: 119468137
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 285
Category: Article
ISSN: 0022-510X
DOI: 10.1016/s0022-510x(09)70788-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FP36-WE-02 Clinical outcomes of short-co

FP36-WE-02 Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

✍ G. Giovannoni; G. Comi; S. Cook; K. Rammohan; P. Rieckmann; P. Soelberg-Sørensen 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

FP36-WE-03 MRI outcomes of short-course

FP36-WE-03 MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study

✍ G. Comi; S. Cook; G. Giovannoni; K. Rammohan; P. Rieckmann; P. Soelberg-Sørensen 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB